Investor News / RNS

Physiomics awarded further contract by Bicycle Therapeutics Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models and its Virtual Tumour™ technology to support the development of cancer treatment regimens and personalised medicine solutions, is pleased to announce that it has been awarded a further contract of undisclosed value by its existing client, Bicycle Therapeutics (“Bicycle”) (the “Project”). The Project is an extension of the work the...

Read More

Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models and its Virtual Tumour™ technology to support the development of cancer treatment regimens and personalised medicine solutions, would like to update its shareholders in light of the rapidly evolving COVID-19 outbreak. The Company’s first concern is of course for the well-being of its employees and to this end, the Company is pleased to confirm that many...

Read More

Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models and its Virtual Tumour™ technology to support the development of cancer treatment regimens and personalised medicine solutions, is pleased to announce that it has been awarded a “Connect” award by the National Institute for Health Research (“NIHR”) Invention for Innovation (“i4i”) programme in respect of the Company’s continued development of its tool for use in...

Read More

Physiomics awarded further contract by Merck Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models and its Virtual Tumour™ technology to support the development of cancer treatment regimens and personalised medicine solutions, is pleased to announce that it has been awarded a further contract of undisclosed value by its existing client Merck KGaA (“Merck”). This contract is an extension of one of the projects awarded and...

Read More

Physiomics awarded two further contracts by Bicycle Therapeutics Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models and its Virtual Tumour™ technology to support the development of cancer treatment regimens and personalised medicine solutions, is pleased to announce that it has been awarded two further contracts of undisclosed value with its existing client Bicycle Therapeutics (“Bicycle”), building on the two projects announced in 2019. Last year...

Read More

Physiomics signs further project agreement with CellCentric Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models to support the development of cancer treatment regimens for the biopharma industry, is delighted to announce that it has been awarded a further contract by existing UK based biotech client, CellCentric.  The value of the contract is not disclosed but is expected to complete in the first half of...

Read More

Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models and its Virtual Tumour™ technology to support the development of cancer treatment regimens for the biopharma industry, is pleased to announce that, following a successful collaboration this year its client Merck KGaA ("Merck") has today committed to an initial tranche of projects for 2020 with an aggregate value of £250,000.  These projects are expected to be...

Read More
})(jQuery)